Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Stocks wavered–while bond yields rose across the board definitively–ahead of tomorrow’s inflation report. The indexes started the day with losses, and wavered after Fed Chair Jerome Powell told ...

The Dow was up 0.1%, but the S&P 500 and the Nasdaq were down 0.1% and 0.4%, respectively. For example, the Invesco S&P 500 ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares.

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

There's one particular industry-leading, tech-forward enterprise -- with a market cap of $434 billion -- that is rapidly ...

Stocks are marking daily gains, but it's nothing to write home about as investors await an update on tariffs while readying ...

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...